TD Private Client Wealth’s Revance Therapeutics, Inc. RVNC Stock Holding History

TD Private Client Wealth’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-34	Closed	-$947	–	1294
2021 Q3	$947	Hold	34	–	–	﹤0.01%	1114
2021 Q2	$1.01K	Hold	34	–	–	﹤0.01%	1109
2021 Q1	$950	Hold	34	–	–	﹤0.01%	1077
2020 Q4	$964	Hold	34	–	–	﹤0.01%	1022
2020 Q3	$855	Hold	34	–	–	﹤0.01%	980
2020 Q2	$830	Hold	34	–	–	﹤0.01%	974
2020 Q1	$503	Hold	34	–	–	﹤0.01%	965
2019 Q4	$552	Buy	+34	New	+$527	﹤0.01%	983

Other funds holding RVNC

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

TD Private Client Wealth's RVNC Position: Q4 2021 in Review

TD Private Client Wealth sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 34 shares — an estimated $947 sold.

TD Private Client Wealth first reported a position in RVNC in Q4 2019 and held it in 8 quarters. The position peaked at $1.01K in Q2 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

TD Private Client Wealth reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
TD Private Client Wealth sold 34 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $947.
TD Private Client Wealth first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 8 quarters.
TD Private Client Wealth's Revance Therapeutics, Inc. position peaked at $1.01K in Q2 2021.
151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on TD Private Client Wealth's 13F filing for Q4 2021, filed 16 Aug 2024.